Association of inflammatory biomarkers with lung cancer in North Indian population by Gaur, Priyanka et al.
Association of  inflammatory biomarkers with lung cancer in North Indian population
Priyanka Gaur1, Sandeep Bhattacharya1, Surya Kant2, R.A.S.  Kushwaha2, Rajiv Garg2, 
Gaurav Singh3, Sarika Pandey2, Supriya Sharma4
1. Department of  Physiology, King George’s Medical University, UP, Lucknow-226010, Uttar Pradesh, India.
2. Department of  Respiratory Medicine, King George’s Medical University, UP, Lucknow -226010, Uttar 
    Pradesh, India.
3. CSIR-Institute of  Genomics and Integrative Biology, Delhi.
4. Department of  Oral Pathology and Microbiology, King George’s Medical University, UP, Lucknow-226010, 
    Uttar Pradesh, India.
 
Abstract:
Background: Lung cancer is characterized by uncontrolled cell growth of  the lung tissues. It is the leading cause of  cancer-re-
lated deaths worldwide. 
Objectives: The study aimed to determine the circulating CRP, TNF-α, IL-6 and IL-8 levels in lung cancer and healthy control 
and also established association between these biomarkers with the smoking status as well as the stages of  the disease. 
Methodology: 51 lung cancer patients and 51 healthy controls were enrolled in this case-control study. The serum levels of  
CRP, TNF-α, IL-6 and IL-8 were measured in lung cancer patients and healthy control groups. 
Results: The levels of  serum CRP, TNF-α, IL-6 and IL-8 were significantly higher in lung cancer patients when compared 
with controls(P<0.0001). The levels of  these biomarkers were also significantly higher in stage iii/iv as compared to stage i/
ii(P<0.001). Significant difference in the levels of  these biomarkers were also found in smoker and non-smoker lung cancer 
patients as compared to controls(P<0.001). 
Conclusion: CRP, TNF-α, IL-6 and IL-8 are the promising biomarkers in the identification of  lung cancer patients. The study 
also supports the association of  inflammatory markers to lung cancer risk. Hence these findings suggest the levels of  these bio-
markers could be a useful tool for guiding the diagnosis of  lung cancer.
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Introduction
Lung cancer is characterized by uncontrolled cell growth 
of  the lung tissues. It is the leading cause of  cancer-relat-
ed mortality worldwide1. Cytokines are soluble polypep-
tides and glycoprotein produced by immune cells ,which 
can act locally or systemically in different cell types and 
triggering signalling pathways responsible for cell acti-
vation, proliferation, growth, differentiation, migration 
and cytotoxicity2,3. Cytokines involved in the activation 
of  immune effectors mechanisms which results to limit 
the tumour growth as well as they also play role in the 
process of  malignant transformation, tumour growth, 
invasion and metastasis4. It has been suggested that the 
characteristic patterns of  cytokines have been found in 
different cancer patients, which can be related to their 
diagnosis, prognosis as well as prediction of  treatment 
responses and survival5. Interleukin 6 (IL-6) is known as a 
multi-functional cytokine which plays a central role in the 
host defense mechanism in regulating immune responses, 
acute phase reactions and haematopoiesis6. It has been 
reported that IL-6 is an autocrine growth factor for renal 
cell carcinoma7,8. IL-6 is produced by other non-haemato-
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poietic tumour cells, including bladder carcinoma9, ovari-
an carcinoma10 and glioblastomas11. It has been suggested 
that circulating pro-inflammatory cytokines may be asso-
ciated with lung cancer. Interleukin 6 (IL-6) and interleu-
kin 8 (IL-8) are expressed in premalignant epithelial cells 
and their expression is associated with a poor prognosis 
of  lung cancer patients12,13. Higher levels of  circulating 
IL-6 and IL-8 were reported in lung cancer14-17, higher 
expression of  IL-8 was reported in small-airway epithe-
lial cells in smokers and  Elevated levels of  serum IL-6 
and IL-8 were also found in smokers18- 20. TNF-α is an 
important immune regulatory factor which has the toxic 
effects on tumor cells and inhibits the tumor growth21. It 
has been supposed that TNF-α could help to maintain 
the metabolic as a protective response to external stress 
whereas excess TNF-α would lead to inflammatory and 
septic shock. CRP is an acute-phase protein, produced in 
the liver in response to elevated cytokine levels after an 
inflammatory stimulus22. It has been found that “acute-
phase response” is also seen in a variety of  diseases such 
as cardiovascular disease, diabetes, systemic inflammato-
ry diseases, some autoimmune disorders and cancer23,24. 
CRP levels have also been used to predict cancer risk, 
detect cancer recurrence and determine prognosis25-27. El-
evated preoperative serum CRP has been identified to be 
a significant prognostic factor in patients with colorectal, 
esophageal and hepatic carcinoma. Previous studies have 
shown that NSCLC Patients with elevated preoperative 
serum CRP levels has experienced worse survival than 
those patients with undetectable levels of  CRP28-30. It is 
well known that chronic inflammation is associated with 
lung carcinogenesis. C-reactive protein (CRP) a systemic 
marker of  chronic inflammation which is associated with 
increased lung cancer risk31-35. Serum biomarkers offer a 
simple, non-invasive, cheap and reliable tool for more ef-
ficient lung cancer management. The serum of  lung can-
cer patients will most likely reveal many proteins that may 
be used as biomarkers. This study aimed to determine the 
association of  circulating biomarkers with the lung can-
cer and also assessed the relationship between these bio-
markers with the smoking and stage of  the lung cancer.
Material and methods
This case control study was conducted between March 
2015 to January 2017 at the Department of  Respiratory 
Medicine, King George’s Medical University, Lucknow, 
India. This study was approved by the ethics committee 
of  the institution and participants gave their written in-
formed consent. A total of  51 histopathologicaly con-
firmed lung cancer patients were enrolled in this study 
after excluding those having other disorders such as 
COPD, asthma, tuberculosis, interstitial lung disease and 
51 healthy controls were also enrolled to compare the se-
rum CRP, IL-6, IL-8, TNF-α level of  both the groups. 
Healthy age and sex matched subjects without pervious 
medical history of  respiratory and other disorders seen 
by their practitioner during regular checkup were recruit-
ed consecutively as controls.
 
Peripheral blood samples of  lung cancer patients and 
controls were collected into the plain vial by venipuncture 
on first admission before chemotherapy. The blood sam-
ple was clotted at room temperature. Serum samples were 
obtained by centrifugation at 3,000 rpm for 10 min and 
stored at -800C until use. Serum Levels of  CRP levels of  
lung cancer patients and healthy controls were estimated.
Serum Levels of  IL-6, IL-8 and TNF-α were determined 
using determined using a commercially available ELISA 
kit according to the manufacturer’s instructions. Data 
were analyzed using Graph Pad Prism version 5 (Graph 
Pad software Inc.; La, Jolla, CA, USA). and the graphs 
were drawn into the excel. All demographic and clinical 
data were expressed as mean ± standard error of  the 
mean (SEM) and percentage. The chi-square test was 
used for categorical data and groups were compared by 
unpaired t-test or one-way analysis of  variance (ANO-
VA). The Bonferroni test was applied for multiple com-
parisons.  p value of  < 0.05 were considered significant.
Results
The demographic and clinical characteristics of  lung can-
cer patients and controls are shown in Table 1. The mean 
age of  the lung cancer patients and control group were not 
showing significant different (p = 0.392).  Out of  51 lung 
cancer patients 41(80.4%) was male and rest 10(19.6%) 
are female. A significant difference was found in smoking 
history of  lung cancer patients and control (p = 0.01). It 
has been observed that the weight and BMI were low-
er in lung cancer patients as compared to controls and 
this difference is statistically significant (p<0.0001). Sta-
tistically significant difference has been observed in the 
pack year of  lung cancer patients as compared to controls 
(p<0.0001)..
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Table 1: Demographic characteristics of Lung cancer patients and control 
 
   Data were expressed in mean ± standard error of the mean (SEM). a Unpaired t-test, b chi-square test.  
   p < 0.05  are considered significant. 
Parameters Lung Cancer (N=51) Controls (N=51) P value 












Height 159.2 ±1.1 158.1±0.95 0.4518 a 
Weight 47.57±1.1 56.18±1.2 < 0.0001a 












Pack Year 36.84 ± 4.95 15.30 ± 1.15 <0.001a 
Histology 
Adenocarcinoma 
Squamous Cell Carcinoma 






















Comparison of  serum levels of  CRP, TNF-α, IL-6 
and IL-8 between Lung Cancer patients healthy con-
trols
The mean level of  CRP in lung cancer patients was 22.43 
± 1.55 and healthy controls was 3.69 ± 0.384, level of  
tnf-α in lung cancer patients was 53.66 ± 3.50 and healthy 
controls was 19.56 ± 0.643, level of  IL-6 in lung cancer 
patients was 44.13 ± 3.86 and healthy controls was 9.97 
± 0.49 and level of  IL-8 in lung cancer patients was 40.28 
± 3.91 and healthy controls was 10.44 ± 0.57. Levels of  
inflammatory cytokines such as CRP TNF-α, IL-6 and 
IL-8 were elevated in lung cancer patients as compared to 
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controls (Fig 1).Significantly difference were found in the serum levels of  CRP, TNF-α, IL-6 and IL-8 as compared 
to control group (P<0.0001)
Comparison of  serum levels of  CRP, TNF-α, IL-6 
and IL-8 among different stages of  lung cancer pa-
tients and healthy control groups: 
The serum CRP,TNF-α , IL-6 and IL-8 levels of  Lung 
Cancer patients in stage III/ IV was significantly higher 
than stage I/ II and healthy controls (Data represented 
in Fig. 2). The study also shows that the significant dif-
ference were found in the serum CRP levels in Stage i/
ii Lung cancer when compared to stage iii/iv Lung can-
cer (p<0.01), stage i/ii Lung cancer  when compared to 
healthy control  (p<0.01) and stage iii/iv Lung cancer 
when compared to healthy controls (p<0.001). The se-
rum TNF-α level of  patients in stage III/IV was higher 
than these in controls and stage I/II.  Significant differ-
ence were obtained in the levels of  TNF-α  in stage iii/
iv Lung cancer when compared to stage i/ii Lung cancer 
(p<0.001) and stage iii/iv Lung cancer when compared 
to  healthy control) (p<0.001). In the serum IL6 levels 
the significant difference was found in stage iii/iv Lung 
cancer when compared to stage i/ii Lung cancer (p<0.01) 
and stage iii/iv lung cancer compared to  healthy con-
trol (p<0.001). significant difference were obtained in 
the Serum IL8 levels of  stage iii/iv Lung cancer when 
compared to stage i/ii Lung cancer (p<0.01) and stage 
iii/iv Lung cancer when compared to  Healthy Control 
(p<0.001).
 
  Figure 1: Comparison of serum CRP, TNF-α, IL6 and IL-8 Levels between lung cancer patient and  
  healthy controls. Data are expressed as mean and compared by unpaired t-test. p-values < 0.05 are  
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Comparison of  serum levels CRP, TNF-α, IL-6 and 
IL-8 between smokers and non- smokers lung can-
cer patients with smokers and non-smokers healthy 
control groups: 
Levels of  serum CRP,TNF-α, IL-6 and IL-8 between 
smokers and non- smokers lung cancer patients and con-
trol were compared ( data represented in fig 3). It has 
been observed that higher serum levels of  CRP, TNF-α, 
IL-6 and IL-8 were observed in smokers as compared to 
non-smokers both in lung cancer patients and controls. In 
the serum CRP levels, Significant difference were found 
in the non-smoker lung cancer patients when compared 
to non smokers controls (p<0.001), Smokers/ Ex-smok-
ers control (p<0.01) and smokers/ Exsmokers lung can-
cer when compared to non-smokers Control (p<0.001), 
Smokers/ Exsmokers Control (p<0.001) and non smok-
ers Lung cancer (p<0.001). Significant difference were 
found in the serum Tnf-α levels of  smokers/ ex- smokers 
lung cancer patients  when compared with non-smokers 
lung cancer (p<0.001) non-smokers control(p<0.001) 
and smokers/ex-smokers control (p<0.001) also signif-
icant difference were found  when non-smokers lung 
cancer patients was compared to non-smokers healthy 
control subjects(p<0.01). Significant difference were 
also found in the serum IL6 levels in smoker/ex-smoker 
Lung cancer patients when compared with non-smokers 
Lung cancer (p<0.001), smokers/ ex-smokers control 
(p<0.001) and non-smokers control (p<0.001). Serum 
IL8 levels also shows the significant difference when 
compared to smoker/ex-smokers Lung cancer patients 
with non-smokers Lung cancer patients (p<0.001), smok-
ers/ ex-smokers control (p<0.001) and  non-smokers 
control (p<0.001).
 
Figure 2: Comparison of Serum CRP, TNF-α, IL-6 and IL-8 between Different Stages of Lung Cancer 
and Healthy Controls. Data presented as mean and compared by one-way analysis of variance 
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Discussion
It has been suggested from the accumulating evidences 
that chronic inflammation is involved in the development 
and progression of  cancer. The immune system of  the 
lung is represented by cells and cytokines, which have 
different functions under physiological conditions. The 
dynamics of  these elements is stable and the ratio of  im-
mune cells and cytokines remains within the normal limits, 
as a result there is no generation of  harmful responses to 
the host. Certain unbalances in these physiologic immune 
responses, caused by lung cancer can serve as biomark-
ers and predictive factors in relation to immunotherapy36. 
Since inflammation can be also triggered by a variety of  
pathogens as well as the environmental factors37. Once 
the lung is vulnerable to these pathogens pathogens and 
gaseous pollutants, the persistent exposure to these fac-
tors can trigger the production of  cytokines that result a 
chronic inflammatory environment which is capable to 
induce cell transformation as well as subsequent tumor 
growth37,38. Various biological processes such as prolif-
eration, differentiation, migration, activation, and cell 
growth are coordinated by cytokines as well as the tumor 
development39,40,41. Cytokines may contribute to tumor 
development by stimulating cell growth and differen-
tiation as well as inhibiting the apoptosis of  abnormal 
cells42. Previous studies have shown that the cytokines in 
several biological fluids such as plasma can reflect vari-
ous diseases including cancer43. The inflammation caused 
by immune system activation is likely linked to carcino-
genesis by promoting angiogenesis and proliferation of  
tumour cells42,12 according to the cytokine profile in the 
tumour microenvironment8,44–47. It is suggested that in-
flammatory cytokines released through inflammatory re-
sponse may promote tumor growth which further with 
advanced non– stimulate the inflammatory response48. 
Previous studies shows that the Serum CRP levels have 
been found to be highly elevated in lung cancer patients 
when compared with healthy control23,49. It has been also 
reported from some previous studies that increased se-
rum CRP levels were found in patients of  small cell lung 
carcinoma50. It has been suggesting that the inflammatory 
cytokines may have the potential to act as biomarkers of  
lung cancer51. In the present study the serum levels of  
CRP, TNF-α, IL-6 and IL-8 seem to be higher in the lung 
cancer patients as compared to healthy controls. These 
findings are similar with some other previously report-
ed studies52,53. Some recent studies suggested that serum 
concentrations of  IL-6 and IL-8 were also found to be 
 
Figure 3: Comparison of Serum CRP, TNF-α, IL-6 and IL-8 Levels Between Smokers and Non-smokers  
lung cancer patients and Smokers and Non-smokers Healthy controls. Data presented as mean and compared  
by one-way analysis of variance (ANOVA) test followed by Bonferroni post-test for multiple  
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increased in lung cancer patients as compared with con-
trol54,55. Serum IL-8 levels were found to be significantly 
elevated in lung cancer patients with respect to controls. 
IL-8 serum levels were also found to be significantly in-
creased in stage III/IV patients as compared with stage 
I/II patients. It has been reported that the serum TNF-α 
levels and IL-8 were found increased along with the ad-
vanced stages of  lung cancer suggesting a possible local 
production of  inflammatory cytokines which is also in 
accordance with some previous studies56. The higher lev-
els of  these inflammation biomarkers were observed in 
smokers/ex-smokers as compared with non-smokers in 
lung cancer patient and control.The higher levels of  in-
flammatory biomarkers in lung cancer patients regardless 
of  smokers or no-smokers indicate that their increase is 
not only due to tobacco use but also affected by lung can-
cer. Since Identification of  biomarkers of  increased can-
cer risk are highly warranted as they may help us in target 
screening programs toward the high risk individuals facil-
itating prevention of  cancer or diagnosis of  cancer at a 
time when curative treatment is still possible. This study 
is an attempt to build a prognostic inflammatory-based 
classifier for the lung cancer. These inflammation cyto-
kines can serve as biomarkers and predictive factors in 
relation to the immunotherapy.
 
Limitation of  the study 
The limitation of  the study is low sample size.  The lev-
els of  these inflammatory biomarkers were not estimated 
before and after the chemotherapy. Further study may be 
done with large sample size and long term follow-up pe-
riod at different time intervals.
 
Conclusion
The present study concluded that the serum CRP, TNF-α, 
IL-6 and IL-8 levels were significantly higher in the pa-
tients with lung cancer as compared to control. The high-
er levels of  all these four inflammation biomarkers were 
observed in smokers as compared with non-smokers. 
This indicates that tobacco smoking play a pivotal role 
in inflammatory processes, thereby contributing to lung 
cancer etiology. It has been demonstrated that Chronic 
inflammation plays an important role in lung cancer. The 
understanding of  the role of  chronic inflammation in the 
pathogenesis of  lung cancer may have an important clin-
ical diagnostic and prognostic implication
Acknowledgement 
We are greatly thankful to department of  Physiology for 
providing necessary facilities for carrying out the study. 
We are also appreciating the patients and the healthy vol-
unteers who were participating in this study.
Conflict of  interest
None declared.
References
1. Siegel R, Ma J, Zou Z, Jemal A .Cancer statistics. CA 
Cancer J Clin. 2014;64(1): 9 PubMed –29.
2. Mack CL.Serum cytokines as biomarkers of  disease and 
clues to pathogenesis. Hepatology. 2007;46 (1):6 PubMed 
–8.
3. Seruga B, Zhang H, Bernstein LJ, Tannock IF.Cytokines 
and their relationship to the symptoms and outcome of  
cancer. Nat Rev Cancer. 2008; 8(11): 887 PubMed –899.
4. Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Cy-
tokines in cancer immunity and immunotherapy. Immunol 
Rev. 2004; 202(1):275–293. PubMed
5. Chang CH, Hsiao CF, Yeh YM, Chang GC, Tsai YH, 
et al.Circulating interleukin-6 level is a prognostic marker 
for survival in advanced nonsmall cell lung cancer patients 
treated with chemotherapy. Int J Cancer. 2013;132(9):1977 
–1985. PubMed
6. Kishimoto T. The biology of  interleukin-6. Blood.1989;74(1):1 
-10. PubMed
7. Koo As, Armstrong C, Bochner B, Shimabukuro T, 
Tso Cl, Dekernion Jb And Belldegrum A. Interleukin-6 
and renal cell cancer production, regulation and growth 
effects,Cancer Immunol. Immunother. 1992;35(2) :97 
PubMed -105.
8.  Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yo-
kokawa K, Sonoda T, Hirano T And Kishimoto T. IL-6 
functions as an autocrine growth factor in renal cell carci-
nomas. FEBS Lett. 1989;250(2):607 PubMed -610.
9.  Rawle Fc, Shields J, Smith Sh, Liescu V, Merken-
schlager M, Beverly Pcl And Callard Re. B cell growth 
and differentiation induced by supernatants of  trans-
formed epitheal cell lines. Eur. J. Immnol. 1989; 16(8):1017 
PubMed -1019.
10. Watson Jm, Sensrntaffar Jl, Berek Js and Martinez-Ma-
za O. Constitutive production of  interleukin 6 by ovarian 
cancer cell lines and by primary ovarian tumor cultures.
Cancer Res. 1990;50(21):6959 PubMed -6965.
11.  Meir Ev, Sawamura Y, Diserens Ac, Hamou Mf  And 
African Health Sciences Vol 19 Issue 2, June, 2019 2153
De Tribolet N. Human glioblastoma cells release inter-
leukin6 in vivo and in vitro. Cancer Res. 1990; 50(20):6683 
PubMed -6688
12. Davalos AR, Coppe JP, Campisi J, et al. Senescent 
cells as a source of  inflammatory factors for tumor pro-
gression. Cancer Metastasis Rev. 2010; 29 (2)273–283.
13.  Seike M, Yanaihara N, Bowman ED, et al. A cyto-
kine gene signature of  the lung adenocarcinoma and its 
tissue environment predicts prognosis. J Natl Cancer Inst. 
2007;99(16):1257 PubMed –1269.
14.  Brichory FM, Misek DE, Yim AM, et al. An immune 
response manifested by the common occurrence of  an-
nexins I and II autoantibodies and high circulating levels 
of  IL-6 in lung cancer. Proc Natl Acad Sci U S A. 2001; 
98(17):9824–9829.
15.  Kaminska J, Kowalska M, Kotowicz B, et al.,Pretreat-
ment serum levels of  cytokines and cytokine receptors in 
patients with non-small cell lung cancer and correlations 
with clinicopathological features and prognosis. M-CSF 
- an independent prognostic factor, Oncology. 2006; 70 (2):115 
PubMed –125.
16.  Orditura M, De Vita F, Catalano G, et al. Elevated 
serum levels of  interleukin-8 in advanced non-small cell 
lung cancer patients: relationship with prognosis. J Inter-
feron Cytokine Res. 2002;22 (11):1129–1135.
17.  Yanagawa H, Sone S, Takahashi Y, et al. Serum levels 
of  interleukin 6 in patients with lung cancer. Br J Cancer. 
1995;71 (5):1095–1098. PubMed
18.  Bermudez EA, Rifai N, Buring J, et al. Interrelation-
ships among circulating interleukin-6, C-reactive protein 
and traditional cardiovascular risk factors in women. Arte-
rioscler Thromb Vasc Biol. 2002;22 (10):1668–1673.
19.  Kluft C, Leuven JA, Helmerhorst FM, et al., Pro-in-
flammatory effects of  oestrogens during use of  oral con-
traceptives and hormone replacement treatment, Vascul 
Pharmacol. 2002;39(3):149–154. PubMed
20.  Takizawa H, Tanaka M, Takami K, et al. Increased 
expression of  inflammatory mediators in small-airway 
epithelium from tobacco smokers. Am J Physiol Lung Cell 
Mol Physiol. 2000;278 (5):L906–L913.
21.  Saito A, Suzuki HI, Horie M, et al. An integrated 
expression profiling reveals target genes of  TGF-beta 
and TNF-alpha possibly mediated by microRNAs in lung 
cancer cells. PLoS One. 2013;8 (2):56587.
22.  Pepys MB, Hirschfield GM. C-reactive protein: a crit-
ical update. J Clin Invest. 2003;111(12) :1805-12. PubMed
23.  Bolayirly M, Turna H, Orhanoglu T, Ozaras R, Ilhan 
M, Ozguroglu M. C-reactive protein as an acute phase 
protein in cancer patients. Med Oncol. 2007;24(2):338 -44. 
24.  Sabatine MS, Morrow DA, Jablonski KA, Rice MM, 
Warnica JW, Domanski MJ, et al, Prognostic significance 
of  the Centers for Disease Control/American Heart As-
sociation high-sensitivity C-reactive protein cut points for 
cardiovascular and other outcomes in patients with sta-
ble coronary artery disease, Circulation. 2007;115(12):1528 
PubMed -36.
25.  Mahmoud FA, Rivera NI. The role of  C-reactive pro-
tein as a prognostic indicator in advanced cancer. Curr 
Oncol Rep. 2002; 4(3):250 PubMed -5.
26.  Wilop S, Crysandt M, Bendel M, Mahnken AH, Osieka 
R, Jost E, Correlation of  C-reactive protein with surviv-
al and radiographic response to first-line platinum-based 
chemotherapy in advanced non-small cell lung cancer, 
Onkologie. 2008; 31(12):665 PubMed -70.   
27.  Chiu HM, Lin JT, Chen TH, Lee YC, Chiu YH, Liang 
JT, et al. Elevation of  C-reactive protein level is associat-
ed with synchronous and advanced colorectal neoplasms 
in men. Am J Gastroenterol. 2008;103(9):2317 PubMed -25.
28.  Koch A, Fohlin H, Sorenson S.Prognostic signifi-
cance of  C-reactive protein and smoking in patients with 
advanced non-small cell lung cancer treated with first-line 
palliative chemotherapy. J Thorac Oncol. 2009; 4 (3):326 
-32. PubMed
29.  lan S, zhiming L, shun L.Clinical significance of  C-re-
active protein in patients with stage I nonsmall cell lung 
cancer. Chin J Oncol. 2011;33 (6) :442-46. PubMed
30.  Hara M, Yonei A, Ayabe T, Tomita M, Nakamura K, 
Onitsuka T. Postoperative serum C-reactive protein levels 
in non-small cell lung cancer patients. Ann Thorac Cardio-
vasc Surg. 2010;16 (2):85-90.
31.  Allin KH, Bojesen SE, Nordestgaard BG.Baseline 
C-reactive protein is associated with incident cancer and 
survival in patients with cancer. J Clin Oncol. 2009;27 
(13):2217 PubMed –2224.
32.  Chaturvedi AK, Caporaso NE, Katki HA, et al. 
C-reactive protein and risk of  lung cancer. J Clin Oncol. 
2010;28 (6):2719 PubMed –2726.
33.  Heikkila K, Ebrahim S, Lawlor DA. A systematic 
review of  the association between circulating concentra-
tions of  C reactive protein and cancer. J Epidemiol Commu-
nity Health. 2007;61(9): 824–833.
34.  Siemes C, Visser LE, Coebergh JW, et al.C-reactive 
protein levels, variation in the C-reactive protein gene, 
and cancer risk: the Rotterdam Study. J Clin Oncol. 2006;24 
(33):5216 PubMed –5222.
35.  Trichopoulos D, Psaltopoulou T, Orfanos P, et al. 
African Health Sciences Vol 19 Issue 2, June, 20192154
Plasma C-reactive protein and risk of  cancer: a prospec-
tive study from Greece. Cancer Epidemiol Biomarkers Prev. 
2006;15(2):381–384.
36.  Domagala-Kulawik J.The role of  the immune system 
in non-small cell lung carcinoma and potential for thera-
peutic intervention. Transl Lung Cancer Res. 2015;4(2):177–
190.
37.   Li J, Lan T, Zhang C, Zeng C, Hou J, et al. Recipro-
cal activation between IL-6/STAT3 and NOX4/Akt sig-
nalings promotes proliferation and survival of  non-small 
cell lung cancer cells. Oncotarget. 2015 ; 6(2):1031–1048
38.   Zhou B, Liu J, Wang ZM, Xi T C-reactive protein, 
interleukin 6 and lung cancer risk: a meta-analysis. PLoS 
One. 2012; 7(8);  PubMed e43075.
39.   Tarrant JM Blood cytokines as biomarkers of  in vivo 
toxicity in preclinical safety assessment: considerations 
for their use. Toxicol Sci. 2010;117(1):4–16. PubMed
40.  Cobos C, Figueroa JA, Mirandola L, Colombo M, 
Summers G, et al.The role of  human papilloma virus 
(HPV) infection in non-anogenital cancer and the prom-
ise of  immunotherapy: a review. Int Rev Immunol. 2014; 33 
(5):383–401. PubMed
41.   Vacchelli E, Aranda F, Bloy N, Buque A, Cremer 
I, et al.,Trial Watch-Immunostimulation with cytokines 
in cancer therapy. Oncoimmunology. 2016; 5(2): PubMed 
e1115942.
42.   Lu H, Ouyang W, Huang C. Inflammation, a key 
event in cancer development. Mol Cancer Res. 2006; 
4(4):221–233. PubMed
43.   Su C, Zhou C, Zhou S, Xu J,Serum cytokine levels 
in patients with advanced non-small cell lung cancer: cor-
relation with treatment response and survival. Med Oncol. 
2011; 28(4):1453–1457. PubMed
44.  Zou W. Immunosuppressive networks in the tumour 
environment and their therapeutic relevance.  Nat Rev 
Cancer. 2005; 5(4):263–74. 
45.   Kinoshita T, Ito H and Miki C. Serum interleukin-6 
level reflects the tumor proliferative activity in patients 
with colorectal carcinoma. Cancer. 1999; 85(12):2526–31. 
PubMed         
46.  Oka M, Iizuka N, Yamamoto K, Gondo T, Abe T, 
Hazama S, Akitomi Y, Koishihara Y, Ohsugi Y, Ooba Y, 
Ishihara T, et al. The influence of  interleukin-6 on the 
growth of  human esophageal cancer cell lines. J Interferon 
Cytokine Res.1996; 16(12): 1001–6.
47.  Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, 
Iwato K, et al. Autocrine generation and requirement of  
BSF-2/IL-6 for human multiple myelomas. Nature.1988; 
332(6159): 83–5. PubMed
48.  Scott HR, McMillan DC, Forrest LM, et al. The sys-
temic inflammatory response, weight loss, performance 
status and survival in patients with inoperable non-small 
cell lung cancer, Br J Cancer. 2002;87(3):264 PubMed -7.
49.  Chung HW, Kim JW, Lee JH, Song Sy, Chung JB, 
Kwon OH, et al. Comparison of  the validity of  three bio-
markers for gastric cancer screening: carcinoembryonic 
antigen, pepsinogens, and high sensitive C-reactive pro-
tein. J Clin Gastroenterol. 2009;43(1):19-26.
50.  Lee JG, Cho BC, Bae MK, Lee CY, Park IK, Kim JD, 
et al. Preoperative C-reactive protein levels are associated 
with tumor size and lymphovascular invasion in resected 
nonsmall cell lung cancer. Lung Cancer. 2009;63 (1):106 
PubMed -10
51.  Hashimoto K, Ikeda Y, Korenaga D, et al, The impact 
of  preoperative serum C-reactive protein on the prog-
nosis of  patients with hepatocellular carcinoma, Cancer. 
2005;103(9): 1856 PubMed -64
52.  Dalaveris E, Kerenidi T, Katsabeki-Katsafli A, et al. 
VEGF, TNF-alpha and 8-isoprostane levels in exhaled 
breath condensate and serum of  patients with lung can-
cer. Lung Cancer. 2009;64 (2):219 PubMed -25.
53.  Tas F, Duranyildiz D, Oguz H, et al. Serum vascu-
lar endothelial growth factor (VEGF) and bcl-2 levels in 
advanced stage non-small cell lung cancer. Cancer Invest. 
2006;24 (6):576-80.
54.  Lagiou P and Trichopoulos D. Inflammatory bio-
markers and risk of  lung cancer. J Natl Cancer Inst. 2011; 
103(14):1073 PubMed -5
55.  Pine SR, Mechanic LE, Enewold L, et al. Increased 
levels of  circulating interleukin 6, interleukin 8, C-reac-
tive protein, and risk of  lung cancer. J Natl Cancer Inst. 
2011;103 (14): 1112-22. PubMed
56.  Boldrini L, Calcinai A, Samaritani E, et al.Tumour 
necrosis factor-alpha and transforming growth fac-
tor-beta are significantly associated with better progno-
sis in non-small cell lung carcinoma: putative relation 
with BCL-2-mediated neovascularisation. Br J Cancer. 
2000;83:480-6 PubMed.
African Health Sciences Vol 19 Issue 2, June, 2019 2155
